About Magnus
We are a neurotechnology company backed by recognized groundbreaking science. We pioneered the first and only FDA-cleared, noninvasive brain stimulation therapy using functional connectivity targeting to bring lasting remission to people living with major depressive disorder (MDD) in just five days.
We’re leading a new era in brain health
Leadership
Our executive team is committed to defining the future of brain health, guided by shared values and a strategic vision to eradicate suffering from brain conditions through groundbreaking science.
Achal Singh Achrol
Chief Executive Officer
Board Member
Dr. Achal Singh Achrol is a neurosurgeon, executive leader, and entrepreneur with 20 years of experience spanning academia, medtech, and biotech. He began his career as neurosurgery faculty with a focus on clinical trials and translational neuroscience research. As a Principal Investigator, he has led clinical trials for noninvasive and minimally-invasive neurosurgical technologies in neuro-oncology, traumatic brain injury, stroke, and neurodegenerative and neuropsychiatric diseases.
Brandon Bentzley, MD, PhD
Co-Founder & Chief Medical Officer
Board Member
Dr. Brandon Bentzley, is co-founder and Chief Scientific Officer of Magnus. His interest in neuroscience led him to the Medical University of South Carolina (MUSC), the birthplace of clinical transcranial magnetic stimulation, where he completed his MD and PhD. He completed his residency and postdoctoral training at Stanford University, focusing on the development of SAINT technology. With over 15 years of experience in developing advanced automated systems, he has published in high-impact peer-reviewed journals, his clinical focus being in treatment-resistant depression and substance abuse disorders.
David Dang
Vice President of Finance
David Dang brings over 20 years of global finance experience across SaaS, marketplace, and consumer technology companies, spanning both large enterprises and startups. His career includes serving as Head of Strategic Finance and Corporate Planning at Lyft, where he led the global strategic finance team across Autonomous Vehicles, Loyalty Membership, Media Advertising, and Strategic Partnerships, and leading Finance, Revenue Operations, and Deal Desk at Calm during a period of rapid growth. Earlier in his career, he held finance leadership roles at Zendesk, GoDaddy, Intuit, and LinkedIn. He received his MBA from the University of Southern California’s Marshall School of Business and a Certificate in Strategy/Risk from Stanford’s Graduate School of Business, after earning his BS in Accounting from the University of La Verne.
Romain Moreau-Gobard
Senior Vice President of Technology
Romain Moreau-Gobard has been integral in building the company’s product and business strategy from inception. He has a distinguished career developing advanced medical imaging software and excels at overseeing the FDA 510(k) pathway to clearance. During his tenure at Magnus, the company achieved FDA clearance and Medicare reimbursements. Previously, he was Director of Engineering at HeartFlow for almost ten years, where he architected a novel software as a medical device (SAMD) and delivered the company’s first FDA-cleared product. He holds 15 US and international patents and a master’s degree in Artificial Intelligence.
Huyen Duong
Vice President of Clinical, Quality and Regulatory
Huyen Duong brings over 25 years of experience in leading clinical, quality, and regulatory affairs organizations at established medical technology companies and early startups. Previously, she was VP of Regulatory Affairs and Quality Assurance at Nesos Corporation, where she defined regulatory and clinical strategies to support global commercialization of their non-invasive neuromodulation platform. Prior to that, as Senior Director at Nevro Corporation, she supported pre- and post-market regulatory activities and managed over 20 clinical investigations. She has also held senior management positions in regulatory affairs at Boston Neuromodulation and Bausch and Lomb.
Matt Wallace
Vice President of Sales
Matthew Wallace leads end-to-end customer engagement across the US markets. Since joining Magnus, he has built the commercial team, managed the healthcare system business, and developed the go-to-market strategy for the SAINT launch in outpatient settings. Prior to Magnus, he was the Vice President of Sales for the Americas and LATAM regions at Insightec. He has held numerous leadership roles launching truly disruptive innovations at medical device companies including Auris Health, iRhythm, Stereotaxis, and Intuitive Surgical.
Dee Kolanek
Vice President of Market Access & Reimbursement
Dee Kolanek brings over 20 years of Market Access & Reimbursement experience, driving patient access to innovative therapies across commercial, Medicare, and employer benefit plan channels. She is responsible for ensuring patients, providers, and payers can navigate coverage pathways with clarity and efficiency at Magnus. Throughout her career, she developed and executed market access strategies for groundbreaking medical devices, securing favorable reimbursement policies, and building strong payer relationships that translate complex policy landscapes into actionable business solutions — work that has played a pivotal role in accelerating product adoption and improving patient access.
Trevor Keating
Vice President of Marketing
Trevor Keating has spent the last decade building profitable businesses in medical devices, digital health, and value-based care. At Magnus, he leads the growth engine that guides people living with mental health needs through a complex reimbursement pathway. He joins from Cubby Beds, where as Vice President of Growth he owned revenue and built a direct-to-family engine reimbursed almost entirely through Medicaid and commercial payers. He was previously Director of Growth at Foodsmart, and earlier supported digital growth for health systems including Bon Secours Mercy Health.
Board of Directors
Heath Lukatch, PhD
Chairman of the Board
Co-Founder and Managing Partner, Red Tree Venture Capital
Heath is a veteran life science investor and entrepreneur with over two decades of experience in venture capital and biotechnology. He is the Founder and Managing Partner of Red Tree Venture Capital, where he focuses on early-stage investments in oncology, neurology, and immunology. Throughout his career, Heath has held senior leadership roles at several global investment firms and has been instrumental in the growth of dozens of life science companies. Before transitioning to venture capital, he was a co-founder and CEO of a biotechnology instrumentation company and worked as a research scientist. Heath holds a PhD in Neuroscience from Stanford University and a BA in Biochemistry from UC Berkeley.
Andrew Firlik, MD
Board Member
Co-Founder and Managing Partner, JAZZ Venture Partners
Andrew is a venture capital investor and entrepreneur with a specialized focus on company building at the intersection of technology and neuroscience. He is a Co-Founder and Managing Partner of JAZZ Venture Partners, leading investments in early and growth-stage technology companies. His professional background includes tenures as a partner at multiple prominent venture firms and as a founder of a publicly traded medical device company. Prior to his career in finance, Andrew was a board-certified neurosurgeon and served as an Assistant Professor of Neurosurgery at Yale and NYU. He has published over 50 medical articles and holds numerous patents. Andrew earned his MD from Weill Cornell Medical College and an MBA from the University of Pittsburgh.
Alex Morgan, MD, PhD
Board Member
Partner, Khosla Ventures
Alex is a physician-scientist and venture capitalist who focuses on the application of data science and artificial intelligence to biology and medicine. He is a Partner at Khosla Ventures, where he leads early and late-stage investments in biotechnology and healthcare. Before entering venture capital, Alex was a research engineer specializing in artificial intelligence and served as a founder or early employee at several startups. As a scientist, he has published over 50 articles at the intersection of computer science and healthcare and has licensed intellectual property to multiple organizations. Alex holds an MD and a PhD in Biomedical Informatics from Stanford University, as well as degrees in physics and biology.
Xingjuan (Jane) Chao, PhD
Board Member
Co-Founder, President & Chief Executive Officer, Ceribell
Jane is a co-founder, President, and Chief Executive Officer of Ceribell, where she has led the company from inception to a publicly traded medical technology business built around rapid, point-of-care EEG for patients in acute care. She has served as Ceribell’s Chief Executive Officer since 2014 and as President since 2016, guiding the company through FDA clearance of the Ceribell System, commercial expansion across US hospitals, and its 2024 Nasdaq listing. Before founding Ceribell, Jane was Principal Manager of Portfolio Management Strategy at Genentech and Senior Strategy Manager at Novartis, following more than five years as a management consultant at McKinsey & Company. Jane holds a BS in Chemistry from Peking University and a PhD in Biophysics from Cornell University, and completed a postdoctoral fellowship at UC San Francisco.
Achal Singh Achrol
Board Member
Chief Executive Officer, Magnus
Dr. Achal Singh Achrol is a neurosurgeon, executive leader, and entrepreneur with 20 years of experience spanning academia, medtech, and biotech. He began his career as neurosurgery faculty with a focus on clinical trials and translational neuroscience research. As a Principal Investigator, he has led clinical trials for noninvasive and minimally-invasive neurosurgical technologies in neuro-oncology, traumatic brain injury, stroke, and neurodegenerative and neuropsychiatric diseases.
Brandon Bentzley, MD, PhD
Board Member
Co-Founder & Chief Medical Officer, Magnus
Dr. Brandon Bentzley, is co-founder and Chief Scientific Officer of Magnus. His interest in neuroscience led him to the Medical University of South Carolina (MUSC), the birthplace of clinical transcranial magnetic stimulation, where he completed his MD and PhD. He completed his residency and postdoctoral training at Stanford University, focusing on the development of SAINT technology. With over 15 years of experience in developing advanced automated systems, he has published in high-impact peer-reviewed journals, his clinical focus being in treatment-resistant depression and substance abuse disorders.
Investors
Our story
Originally developed at Stanford University, SAINT is now licensed exclusively to Magnus Medical to turn a scientific revolution in brain health into real-life impact, offering new hope and healing for millions of people living with brain conditions.
SAINT developed
Psychiatrists and neuroscientists at Stanford’s Brain Stimulation Lab combined targeted therapy with a highly accelerated treatment protocol to stimulate neural networks and rebuild healthy connectivity.
2017Magnus founded
Stanford licensed SAINT exclusively to Magnus for further development and commercialization of the treatment, expanding access for people in need outside of a clinical research environment.
2020Landmark clinical trial
Published in the American Journal of Psychiatry, the results of this landmark double-blind randomized controlled trial were groundbreaking and pivotal in achieving FDA clearance for SAINT.
2021New Technology Add-On Payment
SAINT was granted the first-ever NTAP approval for interventional psychiatry, enabling additional Medicare reimbursement for hospitals.
2023FDA-clearance
SAINT received 510(k) clearance from the U.S. FDA for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement from prior antidepressant medications.
2022Breakthrough designation
The U.S. FDA granted Breakthrough Device Designation to SAINT. This program expedites access to technologies offering more effective treatment for serious conditions.
2021SAINT commercialization
The official shift of SAINT from a research breakthrough to a commercially available clinical treatment began with early adopters of the technology across the U.S.
2024New Tech Ambulatory Payment Classification
SAINT was granted NTAPC status for outpatient care, securing a dedicated Medicare payment pathway to support patient access to high-efficacy care.
2024Series B
This round of funding marked a pivotal step toward scaling SAINT and expanding access to rapid, precision treatment for depression.
2025Featured resources
Discover the science, clinical data, and patient success stories that show the power of SAINT for depression.
Work with purpose
Join our passionate team advancing brain health science with urgency and empathy.